Tracking the therapy: the roles of bioanalysis in AAV-dosed gene therapy trials
The adeno-associated virus (AAV) is the most commonly used viral vector for facilitating the delivery of therapeutic genes into human cells. Sophisticated assays are required for testing AAV-dosed gene therapy, involving measurement of the treatment’s effectiveness throughout the different phases of treatment. The PPD Laboratory services (NC, USA) bioanalytical lab specializes in the development and validation of bioanalytical assays that support AAV gene therapy trials.
This video explains AAV-dosed gene therapy and highlights progression of the AAV vector from being administered to the patient and flowing through the body, to expressing the therapeutic gene. The audience will better understand the progression of AAV vectors and the types of assays that PPD executes at each phase, including:
- Quantitatively monitoring vector levels in the bloodstream
- Identification of antibodies before and after dosing using specialized anti-drug antibody (ADA) assays
- Protein quantification using customized immunochemistry assays
To better understand the progression of AAV vectors and the types of assays PPD provides at each phase of AAV-dosed gene therapy trials, complete the form below.
For more information:
This content has been provided by PPD.
